Eliminating the need for fasting with oral administration of bisphosphonates

References

• PazianasMCooperCEbetinoFHRussellRGGLong-term treatment with bisphosphonates and their safety in postmenopausal osteoporosisTher Clin Risk Manag2010632534320668715
   PubMed Web of Science ®Google Scholar
• EttingerBPressmanAScheinJChanJSilverPConnollyNAlendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuationJ Manag Care Pharm19984488492
   Google Scholar
• RussellRGWattsNBEbetinoFHRogersMJMechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporos Int20081973375918214569
   PubMed Web of Science ®Google Scholar
• PazianasMCompstonJHuangCL-HAtrial fibrillation and bisphosphonate therapyJ Bone Miner Res20102521020091928
   PubMed Web of Science ®Google Scholar
• MitchellDYBarrWHEusebioRARisedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administrationPharm Res20011816617011405286
   PubMed Web of Science ®Google Scholar
• PorrasAGHollandSDGertzBJPharmacokinetics of alendronateClin Pharmacokinet19993631532810384857
   PubMed Web of Science ®Google Scholar
• DunnCJGoaKLRisedronate: a review of its pharmacological properties and clinical use in resorptive bone diseaseDrugs20016168571211368289
   PubMed Web of Science ®Google Scholar
• LinJHChenIWdeLunaFAOn the absorption of alendronate in ratsJ Pharm Sci199483174117467891304
   PubMed Web of Science ®Google Scholar
• BoulencXMartiEJoyeuxHImportance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO 2 monolayers modelBiochem Pharmacol199346159116008240416
   PubMed Web of Science ®Google Scholar
• TwissIMde WaterRden HartighJCytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transportJ Pharm Sci1994836997038071824
   PubMed Web of Science ®Google Scholar
• LinJHBisphosphonates: a review of their pharmacokinetic propertiesBone19961875858833200
   PubMed Web of Science ®Google Scholar
• RuifrokPGMolWEParacellular transport of inorganic and organic ions across the rat ileumBiochem Pharmacol1983326376406830626
   PubMed Web of Science ®Google Scholar
• ThompsonKRogersMJCoxonFPCrockettJCCytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosisMol Pharmacol2006691624163216501031
   PubMed Web of Science ®Google Scholar
• KhalilIAKogureKAkitaHHarashimaHUptake pathways and subsequent intracellular trafficking in nonviral gene deliveryPharmacol Rev200658324516507881
   PubMed Web of Science ®Google Scholar
• KothawalaPBadamgaravERyuSMillerRMHalbertRJSystematic review and meta-analysis of real-world adherence to drug therapy for osteoporosisMayo Clin Proc2007821493150118053457
   PubMed Web of Science ®Google Scholar
• SackettDLSnowJCThe magnitude of adherence and nonadherenceHaynesRBTaylorDWSackettDLCompliance in Health CareBaltimore, MDJohns Hopkins University Press1979
   Google Scholar
• StephensonJNoncompliance may cause half of antihypertensive drug “failures”JAMA199928231331410432015
   PubMed Web of Science ®Google Scholar
• ViswanathanMGolinCEJonesCDMedication Adherence Interventions: Comparative EffectivenessClosing the Quality Gap: Revisiting the State of the Science Evidence Report No 208. (Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No 290-2007-10056-I) AHRQ Publication No 12-E010-EFRockville, MDAgency for Healthcare Research and Quality2012 Available from: http://www.effectivehealthcare.ahrq.gov/reports/final.cfmAccessed September 12, 2013
   Google Scholar
• HansenCPedersenBDKonradsenHAbrahamsenBAnti-osteoporotic therapy in Denmark – predictors and demographics of poor refill compliance and poor persistenceOsteoporos Int2013242079209723179576
   PubMed Web of Science ®Google Scholar
• International Osteoporosis FoundationThe adherence gap: why osteoporosis patients don’t continue with treatment Available from: http://www.iofbonehealth.org/sites/default/files/PDFs/adherence_gap_report_2005.pdfAccessed September 12, 2013
   Google Scholar
• AdachiRJosseRRussellRGIf you don’t take it – it can’t work: the consequences of not being treated or nonadherence to osteoporosis therapyTher Clin Risk Manag2011718119821691589
   PubMed Web of Science ®Google Scholar
• BlanusaMVarnaiVMPiasekMKostialKChelators as antidotes of metal toxicity: therapeutic and experimental aspectsCurr Med Chem2005122771279416305472
   PubMed Web of Science ®Google Scholar
• WhittakerPVanderveenJEDinoviMJKuznesofPMDunkelVCToxicological profile, current use, and regulatory issues on EDTA compounds for assessing use of sodium iron EDTA for food fortificationRegul Toxicol Pharmacol1993184194278128003
   PubMed Web of Science ®Google Scholar
• ForemanHTrujilloTThe metabolism of C14 labeled ethylene diamino tetraacetic acid in human beingsJ Lab Clin Med19544356657113163555
   PubMed Web of Science ®Google Scholar
• JannerMMühlbauerRCFleischHSodium EDTA enhances intestinal absorption of two bisphosphonatesCalcif Tissue Int1991492802831836974
   PubMed Web of Science ®Google Scholar
• Atelvia monograph Available from: http://www.wcrx.com/pdfs/pi/pi_atelvia.pdfAccessed September 12, 2013
   Google Scholar
• PazianasMEpsteinSZaidiMEvaluating the antifracture efficacy of bisphosphonatesRev Recent Clin Trials2009412213019463108
   PubMedGoogle Scholar
• McClungMRMillerPDBrownJPEfficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tabletOsteoporos Int20122326727621947137
   PubMed Web of Science ®Google Scholar
• McClungMRBalskeABurgioDEWenderothDReckerRRTreatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 yearsOsteoporos Int20132430131023079690
   PubMed Web of Science ®Google Scholar
• ChavassieuxPMArlotMERedaCWeiLYatesAJMeunierPJHistomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosisJ Clin Invest1997100147514809294113
   PubMed Web of Science ®Google Scholar
• ReidIRMillerPDBrownJPDenosumab Phase 3 Bone Histology Study GroupEffects of denosumab on bone histomorphometry: the FREEDOM and STAND studiesJ Bone Miner Res2010252256226520533525
   PubMed Web of Science ®Google Scholar